Filing Flows › Lineage Cell Therapeutics (LCTX) › Stock forecast & fair value
Lineage Cell Therapeutics (LCTX) stock forecast and price target
Lineage Cell Therapeutics (LCTX) trades at $1.02. 6 analysts' median price target is $4.50 (+341%), from $3.00 to $9.00.
Lineage Cell Therapeutics' latest quarter
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for LCTX stock?
The median of 6 analysts' 12-month targets is $4.50, +341% from $1.02; the range is $3.00 to $9.00. The average rating is strong buy.
Does Lineage Cell Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 67% of the quarters on record.
Is LCTX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.